Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
98 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Aspergillosis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Aspergillosis - Pipeline Review, H1 2016', provides an overview of the Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Aspergillosis - The report reviews pipeline therapeutics for Aspergillosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Aspergillosis therapeutics and enlists all their major and minor projects - The report assesses Aspergillosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Aspergillosis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Aspergillosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Aspergillosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Aspergillosis Overview 10 Therapeutics Development 11 Pipeline Products for Aspergillosis - Overview 11 Pipeline Products for Aspergillosis - Comparative Analysis 12 Aspergillosis - Therapeutics under Development by Companies 13 Aspergillosis - Therapeutics under Investigation by Universities/Institutes 15 Aspergillosis - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Aspergillosis - Products under Development by Companies 20 Aspergillosis - Products under Investigation by Universities/Institutes 21 Aspergillosis - Companies Involved in Therapeutics Development 22 Amplyx Pharmaceuticals, Inc. 22 Astellas Pharma Inc. 23 Biomar Microbial Technologies 24 Cidara Therapeutics, Inc. 25 F2G Ltd 26 Hsiri Therapeutics, LLC 27 iCo Therapeutics Inc. 28 Matinas BioPharma Holdings, Inc. 29 Merck & Co., Inc. 30 Nanomerics Ltd 31 Novabiotics Limited 32 Pulmatrix, Inc. 33 Pulmocide Ltd 34 Scynexis, Inc. 35 Sealife PHARMA GMBH 36 Sigma-Tau S.p.A. 37 TGV-Laboratories 38 Vical Incorporated 39 Aspergillosis - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Target 41 Assessment by Mechanism of Action 43 Assessment by Route of Administration 45 Assessment by Molecule Type 47 Drug Profiles 49 amphotericin B - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 amphotericin B - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 amphotericin B - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 amphotericin B - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 APX-001 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ASP-9726 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Aspergillus fumigatus vaccine - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 C-001 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 C-016 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 F-901318 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 itraconazole - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 KB-425796C - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 MDN-0018 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Myc-102 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 NP-339 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 NP-525 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 PC-945 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 posaconazole - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 PTX-3 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 SCY-078 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 SLP-0901 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 SLP-0904 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Small Molecule for Aspergillosis - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecules for Aspergillosis and Candidiasis - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Small Molecules for Fungal Infections - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Small Molecules for Fungal Infections - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Small Molecules to Inhibit ABC Transporter for Fungal Infections - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 VL-2397 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Aspergillosis - Recent Pipeline Updates 80 Aspergillosis - Dormant Projects 87 Aspergillosis - Discontinued Products 89 Aspergillosis - Product Development Milestones 90 Featured News & Press Releases 90 Mar 30, 2016: FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis 90 Mar 07, 2016: Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397 90 Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections 91 Jan 06, 2016: FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis 91 Dec 17, 2015: Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA 92 Nov 30, 2015: F2G to Participate in the Adaptive Pathways Pilot Programme 93 Sep 21, 2015: SCYNEXIS Presents Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015 93 Sep 15, 2015: Vical to Present Preclinical Data at ICAAC 2015 Meeting for Its Novel Antifungal Drug Candidate VL-2397 94 Aug 19, 2015: FDA Grants Qualified Infectious Disease Product Designation to VL-2397, Vical's Antifungal Product Candidate 95 Mar 25, 2015: Vical Expands Infectious Disease Portfolio With Novel Antifungal From Astellas 95 Appendix 97 Methodology 97 Coverage 97 Secondary Research 97 Primary Research 97 Expert Panel Validation 97 Contact Us 97 Disclaimer 98
List of Tables
Number of Products under Development for Aspergillosis, H1 2016 11 Number of Products under Development for Aspergillosis - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Comparative Analysis by Unknown Stage Development, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Investigation by Universities/Institutes, H1 2016 21 Aspergillosis - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016 22 Aspergillosis - Pipeline by Astellas Pharma Inc., H1 2016 23 Aspergillosis - Pipeline by Biomar Microbial Technologies, H1 2016 24 Aspergillosis - Pipeline by Cidara Therapeutics, Inc., H1 2016 25 Aspergillosis - Pipeline by F2G Ltd, H1 2016 26 Aspergillosis - Pipeline by Hsiri Therapeutics, LLC, H1 2016 27 Aspergillosis - Pipeline by iCo Therapeutics Inc., H1 2016 28 Aspergillosis - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 29 Aspergillosis - Pipeline by Merck & Co., Inc., H1 2016 30 Aspergillosis - Pipeline by Nanomerics Ltd, H1 2016 31 Aspergillosis - Pipeline by Novabiotics Limited, H1 2016 32 Aspergillosis - Pipeline by Pulmatrix, Inc., H1 2016 33 Aspergillosis - Pipeline by Pulmocide Ltd, H1 2016 34 Aspergillosis - Pipeline by Scynexis, Inc., H1 2016 35 Aspergillosis - Pipeline by Sealife PHARMA GMBH, H1 2016 36 Aspergillosis - Pipeline by Sigma-Tau S.p.A., H1 2016 37 Aspergillosis - Pipeline by TGV-Laboratories, H1 2016 38 Aspergillosis - Pipeline by Vical Incorporated, H1 2016 39 Assessment by Monotherapy Products, H1 2016 40 Number of Products by Stage and Target, H1 2016 42 Number of Products by Stage and Mechanism of Action, H1 2016 44 Number of Products by Stage and Route of Administration, H1 2016 46 Number of Products by Stage and Molecule Type, H1 2016 48 Aspergillosis Therapeutics - Recent Pipeline Updates, H1 2016 80 Aspergillosis - Dormant Projects, H1 2016 87 Aspergillosis - Dormant Projects (Contd..1), H1 2016 88 Aspergillosis - Discontinued Products, H1 2016 89
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
